Literature DB >> 27104896

Clinical Utility of Amyloid PET Imaging in the Differential Diagnosis of Atypical Dementias and Its Impact on Caregivers.

Mohamed Reda Bensaïdane1, Jean-Mathieu Beauregard2, Stéphane Poulin1, François-Alexandre Buteau2, Jean Guimond2, David Bergeron1, Louis Verret1,3, Marie-Pierre Fortin1, Michèle Houde1, Rémi W Bouchard1,3, Jean-Paul Soucy4, Robert Laforce1,3.   

Abstract

Recent studies have supported a role for amyloid positron emission tomography (PET) imaging in distinguishing Alzheimer's disease (AD) pathology from other pathological protein accumulations leading to dementia. We investigated the clinical utility of amyloid PET in the differential diagnosis of atypical dementia cases and its impact on caregivers. Using the amyloid tracer 18F-NAV4694, we prospectively scanned 28 patients (mean age 59.3 y, s.d. 5.8; mean MMSE 21.4, s.d. 6.0) with an atypical dementia syndrome. Following a comprehensive diagnostic workup (i.e., history taking, neurological examination, blood tests, neuropsychological evaluation, MRI, and FDG-PET), no certain diagnosis could be arrived at. Amyloid PET was then conducted and classified as positive or negative. Attending physicians were asked to evaluate whether this result led to a change in diagnosis or altered management. They also reported their degree of confidence in the diagnosis. Caregivers were met after disclosure of amyloid PET results and completed a questionnaire/interview to assess the impact of the scan. Our cohort was evenly divided between positive (14/28) and negative (14/28) 18F-NAV4694 cases. Amyloid PET resulted in a diagnostic change in 9/28 cases (32.1%: 17.8% changed from AD to non-AD, 14.3% from non-AD to AD). There was a 44% increase in diagnostic confidence. Altered management occurred in 71.4% (20/28) of cases. Knowledge of amyloid status improved caregivers' outcomes in all domains (anxiety, depression, disease perception, future anticipation, and quality of life). This study suggests a useful additive role for amyloid PET in atypical cases with an unclear diagnosis beyond the extensive workup of a tertiary memory clinic. Amyloid PET increased diagnostic confidence and led to clinically significant alterations in management. The information gained from that test was well received by caregivers and encouraged spending quality time with their loved ones.

Entities:  

Keywords:  Alzheimer variants; Alzheimer’s disease; amyloid PET imaging; atypical dementia; caregivers; clinical utility; differential diagnosis; frontotemporal lobar degeneration; impact; primary progressive aphasia

Mesh:

Substances:

Year:  2016        PMID: 27104896     DOI: 10.3233/JAD-151180

Source DB:  PubMed          Journal:  J Alzheimers Dis        ISSN: 1387-2877            Impact factor:   4.472


  17 in total

1.  Association of Amyloid Positron Emission Tomography With Changes in Diagnosis and Patient Treatment in an Unselected Memory Clinic Cohort: The ABIDE Project.

Authors:  Arno de Wilde; Wiesje M van der Flier; Wiesje Pelkmans; Femke Bouwman; Jurre Verwer; Colin Groot; Marieke M van Buchem; Marissa Zwan; Rik Ossenkoppele; Maqsood Yaqub; Marleen Kunneman; Ellen M A Smets; Frederik Barkhof; Adriaan A Lammertsma; Andrew Stephens; Erik van Lier; Geert Jan Biessels; Bart N van Berckel; Philip Scheltens
Journal:  JAMA Neurol       Date:  2018-09-01       Impact factor: 18.302

2.  Impact of Amyloid PET Imaging in the Memory Clinic: A Systematic Review and Meta-Analysis.

Authors:  Yat-Fung Shea; Warren Barker; Maria T Greig-Gusto; David A Loewenstein; Ranjan Duara; Steven T DeKosky
Journal:  J Alzheimers Dis       Date:  2018       Impact factor: 4.472

3.  Utility of Amyloid PET Scans in the Evaluation of Patients Presenting with Diverse Cognitive Complaints.

Authors:  Yat-Fung Shea; Warren Barker; Maria T Greig-Gusto; David A Loewenstein; Steven T DeKosky; Ranjan Duara
Journal:  J Alzheimers Dis       Date:  2018       Impact factor: 4.472

4.  Patient and Caregiver Assessment of the Benefits From the Clinical Use of Amyloid PET Imaging.

Authors:  Rafid Mustafa; Jared R Brosch; Gil D Rabinovici; Bradford C Dickerson; Maria C Carrillo; Bradley S Glazier; Sujuan Gao; Martha Tierney; Keith N Fargo; Mary G Austrom; Susan De Santi; David G Clark; Liana G Apostolova
Journal:  Alzheimer Dis Assoc Disord       Date:  2018 Jan-Mar       Impact factor: 2.703

5.  Patient and caregiver reactions to clinical amyloid imaging.

Authors:  Joshua D Grill; Chelsea G Cox; Sarah Kremen; Mario F Mendez; Edmond Teng; Jill Shapira; John M Ringman; Liana G Apostolova
Journal:  Alzheimers Dement       Date:  2017-02-04       Impact factor: 21.566

Review 6.  Novel Tracers and Radionuclides in PET Imaging.

Authors:  Christian Mason; Grayson R Gimblet; Suzanne E Lapi; Jason S Lewis
Journal:  Radiol Clin North Am       Date:  2021-09       Impact factor: 1.947

7.  Clinical impact of amyloid PET using 18F-florbetapir in patients with cognitive impairment and suspected Alzheimer's disease: a multicenter study.

Authors:  Hiroshi Matsuda; Kyoji Okita; Yumiko Motoi; Toshiki Mizuno; Manabu Ikeda; Nobuo Sanjo; Koji Murakami; Taiki Kambe; Toshiki Takayama; Kei Yamada; Takashi Suehiro; Keiko Matsunaga; Takanori Yokota; Ukihide Tateishi; Yoko Shigemoto; Yukio Kimura; Emiko Chiba; Takahiro Kawashima; Yui Tomo; Hisateru Tachimori; Yuichi Kimura; Noriko Sato
Journal:  Ann Nucl Med       Date:  2022-10-04       Impact factor: 2.258

8.  Patient Stakeholder Versus Physician Preferences Regarding Amyloid PET Testing.

Authors:  Melissa J Armstrong; Gary S Gronseth; Gregory S Day; Carol Rheaume; Slande Alliance; C D Mullins
Journal:  Alzheimer Dis Assoc Disord       Date:  2019 Jul-Sep       Impact factor: 2.703

9.  Incremental value of amyloid-PET versus CSF in the diagnosis of Alzheimer's disease.

Authors:  Matteo Cotta Ramusino; Valentina Garibotto; Ruggero Bacchin; Daniele Altomare; Alessandra Dodich; Frederic Assal; Aline Mendes; Alfredo Costa; Michele Tinazzi; Silvia D Morbelli; Matteo Bauckneht; Agnese Picco; Massimo E Dottorini; Cristina Tranfaglia; Lucia Farotti; Nicola Salvadori; Davide Moretti; Giordano Savelli; Anna Tarallo; Flavio Nobili; Maura Parapini; Carlo Cavaliere; Elena Salvatore; Marco Salvatore; Marina Boccardi; Giovanni B Frisoni
Journal:  Eur J Nucl Med Mol Imaging       Date:  2019-08-06       Impact factor: 9.236

10.  Critical review of the Appropriate Use Criteria for amyloid imaging: Effect on diagnosis and patient care.

Authors:  Liana G Apostolova; Janelle M Haider; Naira Goukasian; Gil D Rabinovici; Gael Chételat; John M Ringman; Sarah Kremen; Joshua D Grill; Lucas Restrepo; Mario F Mendez; Daniel H Silverman
Journal:  Alzheimers Dement (Amst)       Date:  2016-12-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.